📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. (2020)

First Author: Camu W

Attributed to: A Programme for ALS Care in Europe (ALS-CarE) funded by ESRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2020.102844

PubMed Identifier: 32651161

Publication URI: http://europepmc.org/abstract/MED/32651161

Type: Journal Article/Review

Volume: 59

Parent Publication: EBioMedicine

ISSN: 2352-3964